Radiotherapy for COVID-19:

Boon, Ian S; Yong, T.P.T. Au; Boon, Cheng

doi:10.1016/j.radonc.2020.05.046

Cited by 7 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The COVID-19 Rapid Letter by Boon et al urged caution and careful examination of the evidence and logistics of low-dose radiotherapy in COVID-19 patients. 1 This is exactly what was requested in the March 20, 2020, Cuttler to Hahn letter to the FDA 2 and what has occurred since late April 2020 when the first phase I/II clinical trial was approved at the Winship Cancer Institute, Emory University Hospital. 3 The preprint of day-7 interim results by the investigators concluded, “In a small pilot trial of 5 oxygen-dependent patients with COVID-19 pneumonia, low-dose whole-lung radiation led to rapid improvement in clinical status, encephalopathy, and radiographic infiltrates without acute toxicity or worsening the cytokine storm.…”

mentioning

confidence: 63%

“…6 The optimal radiation dose will be determined in the trials; however, the investigators are using a single dose in the range from 0.3 to about 1 Gy. Considering the typical radiotherapy for lung cancer, a daily fraction of 2 Gy for 6 weeks (60 Gy), we question the fearful concerns raised in the primum non nocere letter by Boon et al 1 regarding this radiotherapy for severe COVID-19 disease.…”

mentioning

confidence: 89%

“…This human evidence contradicts the concerns raised by Boon et al about delayed health effects. 1 In conclusion, we believe it would be unethical not to investigate radiotherapy as a potential remedy against COVID-19 induced pneumonia.…”

mentioning

confidence: 93%

See 2 more Smart Citations

Unethical not to Investigate Radiotherapy for COVID-19

Cuttler¹,

Bevelacqua²,

Mortazavi

2020

Dose-Response

View full text Add to dashboard Cite

The primum non nocere letter by Boon et al. urged caution and careful examination of the evidence and logistics of low-dose radiotherapy in COVID-19 patients. This is exactly what was requested in March and what has occurred since late April 2020 when the first phase I/II clinical trial was approved at the Winship Cancer Institute, Emory University Hospital. The preprint of day-7 interim results by the investigators concluded, “In a small pilot trial of 5 oxygen-dependent patients with COVID-19 pneumonia, low-dose whole-lung radiation led to rapid improvement in clinical status, encephalopathy, and radiographic infiltrates without acute toxicity or worsening the cytokine storm. Low-dose whole-lung radiation appears to be safe, shows early promise of efficacy, and warrants larger prospective trials.” Preliminary results from another clinical trial gave similar results. In conclusion, the authors believe it would be unethical not to investigate radiotherapy as a potential remedy against COVID-19 induced pneumonia

show abstract

mentioning

confidence: 63%

mentioning

confidence: 89%

See 1 more Smart Citation

Unethical not to Investigate Radiotherapy for COVID-19

Cuttler¹,

Bevelacqua²,

Mortazavi

2020

Dose-Response

View full text Add to dashboard Cite

show abstract

“…Delivering radiotherapy by giving quality assurance is impossible as the system conditions of portable X-ray machines delivering low-dose radiation therapy are not compatible. The concept of being as low as reasonably achievable is the basis of the radiation protection approach[ 61 ]. Targeting the whole lung requires vast knowledge about the biological mechanisms and hence deliverance of a low dose for an appropriate target volume is highly challenging.…”

Section: Limitations/ Future Improvements On Using X-rays For the Dia...mentioning

confidence: 99%

Impact of X-radiation in the management of COVID-19 disease

Mohan¹,

Nandhini²,

Raavi³

et al. 2022

WJR

View full text Add to dashboard Cite

Coronaviruses are a diverse group of viruses that infect both animals and humans. Even though the existence of coronavirus and its infection to humans is not new, the 2019-novel coronavirus (nCoV) caused a major burden to individuals and society i.e. , anxiety, fear of infection, extreme competition for hospitalization, and more importantly financial liability. The nCoV infection/disease diagnosis was based on non-specific signs and symptoms, biochemical parameters, detection of the virus using reverse-transcription polymerase chain reaction (RT-PCR), and X-ray-based imaging. This review focuses on the consolidation of potentials of X-ray-based imaging modality [chest-X radiography (CXR) and chest computed tomography (CT)] and low-dose radiation therapy (LDRT) for screening, severity, and management of COVID-19 disease. Reported studies suggest that CXR contributed significantly toward initial rapid screening/diagnosis and CT- imaging to monitor the disease severity. The chest CT has high sensitivity up to 98% and low specificity for diagnosis and severity of COVID-19 disease compared to RT-PCR. Similarly, LDRT compliments drug therapy in the early recovery/Less hospital stays by maintaining the physiological parameters better than the drug therapy alone. All the results undoubtedly demonstrated the evidence that X-ray-based technology continues to evolve and play a significant role in human health care even during the pandemic.

show abstract

“…A recent letter by Boon et al (2020) proposes a cautious approach and raises a number of concerns, among which the insufficiently known COVID-19 pneumonia pathophysiology, the risks of secondary malignancy, the difficulty of getting the informed consent due to the state of the patients, the difficult logistics of radiotherapy and radiation protection in intensive care units, and finally the lack in precision of whole-lung irradiation. A recent editorial by Tharmalingam et al (2020) also suggests a cautious approach and raises several concerns, such as the highly atypical pathogenesis of SARS-CoV-2, the narrow character of any LDRT window and the risk of serious disruptions to regular cancer radiotherapy delivery if significant material and human resources would misdirected toward LDRT on COVID-19 pneumonia patients.…”

mentioning

confidence: 99%